Publications by authors named "Lea N Baer"
Article Synopsis
- CDK4/6 inhibitors like ribociclib, when combined with a new endocrine therapy (ET), significantly improve progression-free survival (PFS) for patients with hormone receptor-positive, HER2-negative metastatic breast cancer that has progressed on prior therapies.
- In a phase II, double-blind trial, patients who switched their ET and received ribociclib showed a PFS median of 5.29 months, compared to 2.76 months for those on placebo.
- The study highlights the effectiveness of modifying treatment in advanced breast cancer, demonstrating a notable benefit in PFS, with rates at 6 and 12 months being much higher for the ribociclib group.
An increased risk of posttransplant malignancy has been consistently reported following various solid organ transplants. The malignancies most commonly encountered are non-melanoma skin cancers, carcinomas of lung or breast and posttransplant lymphoproliferative disorders. Angiosarcoma, an uncommon vascular mesenchymal neoplasm, is rare in the posttransplant setting.
View Article and Find Full Text PDFComposite plasma cell neoplasm (PCN) and low grade B-cell lymphoma (B-NHL) in the bone marrow are uncommon and raise the differential diagnosis of B-NHL with plasmacytic differentiation and PCN with lymphoplasmacytic morphology. This can be a challenging differential diagnosis, and the distinctions are important because of differences in management. We report five cases of composite PCN with B-NHL or clonal B-cell infiltrates involving the bone marrow.
View Article and Find Full Text PDF